Drug development for the treatment of systemic lupus erythematosus (SLE) has largely focused on B-cell therapies. A greater understanding of the immunopathogenesis of SLE coupled with advanced bioengineering has allowed for clinical trials centered on other targets for SLE therapy. The authors discuss the benefits and shortcomings of focusing on T-cell-directed therapies in SLE and lupus nephritis clinical trials.
NavarraSVGuzmánRMGallacherAE. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet2011; 377: 721–331.
2.
FurieRPetriMZamaniO. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum2011; 63: 3918–3930.
3.
MakAKowN. The pathology of T Cells in systemic lupus erythematosus. J Immunol Res2014; 2014: 1–8.
4.
WangXHuangWMiharaMSinhaJDavidsonA. Mechanism of action of combined short-term CTLA4IG and Anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol2002; 168: 2046–2053.
5.
TsokosG. Systemic lupus erythematosus. N Engl J Med2011; 365: 2110–2121.
6.
BoumpasDFurieRManziS. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum2003; 48: 719–727.
7.
NishiokaYLipskyPE. The role of CD40-CD40 ligand interaction in human T cell-B cell collaboration. J Immunol1994; 153: 1027–1036.
8.
HuangWSinhaJNewmanJ. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum2002; 46: 1554–1562.
9.
DavisJCJrTotoritisMCRosenbergJSklenarTAWofsyD. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol2001; 28: 95–101.
10.
KalunianKCDavisJCJrMerrillJTTotoritisMCWofsyD. IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum2002; 46: 3251–3258.
11.
Chamberlain C, Urowitz M, Soranson J, et al. Repeated administration of Dapirolizumab pegol (DZP) appears safe and well tolerated in patients with systemic lupus erythematosus (SLE) and is accompanied by an improvement in disease activity: Results from a phase 1 study (abstract). Arthritis Rheumatol 2015; 67.
12.
McCoyKDLe GrosG. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol1999; 77: 1–10.
13.
FinckBLinsleyPWofsyD. Treatment of murine lupus with CTLA4Ig. Science1994; 265: 1225–1227.
14.
MerrillJBurgos-VargasRWesthovensR. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum2010; 62: 3077–3087.
15.
FurieRNichollsKChengT. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol2014; 66: 379–389.
16.
WofsyDHillsonJDiamondB. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum2012; 64: 3660–3665.
17.
WofsyDAACagnoliPCChathamWW. Treatment of lupus nephritis with abatacept plus low-dose cyclophosphamide followed by azathioprine (the Euro-Lupus Regimen): Twenty-four week data from a double-blind controlled trial. Arthritis Rheum2013; 65: 884–884.
18.
DaikhDWofsyD. Cutting Edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol2001; 166: 2913–2916.
19.
LiuZZhangHLiuZ. Multitarget therapy for induction treatment of lupus nephritis. Ann Intern Med2015; 162: I–24.
20.
LoMSTsokosGC. T Cells in systemic lupus erythematosus. The Rheumatologist2011, pp. 1–8.
21.
BarronLDoomsHHoyerKK. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol2010; 185: 6426–6430.
22.
HeJZhangXYuDLiZ. Safety and efficiency of low-dose interleukin-2 treatment in systemic lupus erythematosus (abstract). Ann Rheum Dis2015; 74: 1075.3–1076.
23.
ChongARezaiKGebelH. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation1996; 61: 140–145.
24.
TamLLiEWongCLamCSzetoC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus2004; 13: 601–604.
25.
WangHCuiTHouF. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study. Lupus2008; 17: 638–644.
26.
AllisonAEuguiE. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology2000; 47: 85–118.
27.
FurieRToderKZapantisE. Lessons learned from the clinical trials of novel biologics and small molecules in lupus nephritis. Sem Nephrol2015; 35: 509–520.
28.
ChanTLiFTangC. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med2000; 343: 1156–1162.
29.
GinzlerEDooleyMAranowC. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med2005; 353: 2219–2228.
30.
AppelGContrerasGDooleyM. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol2009; 20: 1103–1112.
31.
DooleyMAJayneDGinzlerEM. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med2011; 365: 1886–1895.
32.
HoussiauFAD'CruzDSangleS. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis2010; 69: 2083–2089.
33.
SthoegerZMDayanMTcherniackA. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol2003; 131: 385–392.
34.
LugerDDayanMZingerH. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol2004; 24: 579–590.
35.
MauermannNSthoegerZZingerH. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patient. Clin Exp Immunol2004; 137: 513–520.
36.
SharabiAZingerHZborowskyM. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by upregulating CD4+CD25+ cells and TGF-β. Proc Natl Acad Sci2006; 103: 8810–8815.
37.
UrowitzMIsenbergDWallaceD. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: Results of phase II study. Lupus Sci Med2015; 2: e000104–e000104.
38.
PageNGrosFSchallN. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis2010; 70: 837–843.
39.
ZimmerRScherbarthHRilloOGomez-ReinoJJMullerS. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: A randomized double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis2013; 72: 1830–1835.
40.
LourençoEWongMHahnBPalma-DiazMSkaggsB. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol2014; 66: 674–685.
41.
JayneDAppelGChanTBarkayHWeissRWofsyD. LB0003 A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis2013; 72: A164–A164.
42.
O'LoghlenAPérez-MorgadoMISalinasMMartínME. N-acetyl-cysteine abolishes hydrogen peroxide-induced modification of eukaryotic initiation factor 4F activity via distinct signalling pathways. Cell Signal2006; 18: 21–31.
43.
SuwannarojS1LagooAKeislerDMcMurrayRW. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus2001; 10: 258–265.
44.
LaiZHanczkoRBonillaE. N -acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum2012; 64: 2937–2946.
